San Diego-dependent Viking Therapeutics marked by itself as a significant competitor in the weight loss drug market place in February following revealing promising details from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered to be a weekly injection As well as in Ma